New York, USA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Renal cancer, also known as kidney cancer, is a disease where malignant (cancer) cells form in the tissues of the kidneys. Smoking, obesity, hypertension, and chronic kidney disease contribute to higher renal cancer rates.
The global incidence of renal cancer has also been rising, partly due to improved diagnostic techniques and aging populations. DelveInsight’s ' Renal Cancer Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline renal cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the renal cancer pipeline domain. Key Takeaways from the Renal Cancer Pipeline Report DelveInsight’s renal cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for renal cancer treatment.
Key renal cancer companies such as Genentech, Allogene Therapeutics, Merck & Co. Inc, Mabwell (Shanghai) Bioscience Co., Ltd.
, Beijing Scitech-Mq Pharmaceuticals Limited, Jiangsu Hansoh Pharmaceutical Co., Ltd., Arcus Biosciences, Infinity Pharmaceuticals, Janux Therapeutics, CRISPR Therapeutics, Arsenal Biosciences, NGM Biopharmaceuticals, Molecure NiKang Therapeutics, Inc.
, ProfoundBio, RemeGen, and others are evaluatin.
